{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00186914",
      "OrgStudyIdInfo": {
        "OrgStudyId": "STOD"
      },
      "Organization": {
        "OrgFullName": "St. Jude Children's Research Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation",
      "OfficialTitle": "Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation: A Phase I Study"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2008",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 1999"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "November 2001",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "January 2008",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "September 9, 2005",
      "StudyFirstSubmitQCDate": "September 9, 2005",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 16, 2005",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "March 3, 2015",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "March 4, 2015",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "St. Jude Children's Research Hospital",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Drexel University",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Wayne State University",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Osteodysplasia or poorly formed bones, \"brittle bones\" is a genetic disease with no known proven treatments. Some forms of osteodysplasia may cause severe disability and even death.\n\nEligible patients were limited to those children with Osteodysplasia who had undergone a previous allogeneic bone marrow transplant at St. Jude. The study intervention involved an infusion of a specified number of ex vivo expanded stromal cells obtained from the bone marrow of the same donor from whom they received their primary transplant procedure. These bone marrow stromal cells can become bone-forming cells, called osteoblasts. Participants then received 2 infusions of ex vivo expanded, gene marked cells not less than 6 months after bone marrow transplantation. The second cell infusion occurred between 14 to 21 days after the first infusion in the absence of toxicity. The goal of the study was to evaluate the safety and toxicity of these infusions.",
      "DetailedDescription": "To determine whether these ex vivo expanded, gene marked marrow stromal cells will engraft in the recipient's bone, bone marrow, and/or skin.\nTo begin to investigate whether high proliferative mesenchymal progenitor cells can be expanded ex vivo and retain their progenitor potential in vivo.\nTo begin to investigate whether ex vivo expanded bone marrow stromal cells can ameliorate the skeletal dysplasias associated with various genetic disorders."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Osteodysplasia"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Bone marrow transplant",
          "bone marrow stromal cells",
          "allogeneic transplant",
          "Osteodysplasia",
          "Osteogenesis imperfecta",
          "Gene marking",
          "Stromal cell"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "8",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "1",
            "ArmGroupType": "Other",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Marrow stromal cell infusion"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Marrow stromal cell infusion",
            "InterventionDescription": "This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions.\n\nAs the stromal cells will be obtained from the original stem cell donor, no conditioning is required.\n\nPatients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10^6 MSC/kg and the second dose of cells will be 5x10^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "1"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Gene marking",
                "mesenchymal cells"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "To evaluate the safety of the stromal cell infusion",
            "PrimaryOutcomeTimeFrame": "June 2001"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatients with an appropriate genetic disorder who have had an allogeneic bone marrow transplant and currently maintain complete or mixed hematopoietic chimerism\nPatient must be < or equal to 18Kg\n\nExclusion Criteria:\n\nPresence of infection\nPresence of GVHD (graft versus host disease)or the need for prophylaxis\nConcurrent participation in any investigational study that could potentially confound the interpretation of the safety parameters being investigated in this study.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Kimberly Kasow, DO",
            "OverallOfficialAffiliation": "St. Jude Children's Research Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "St. Jude Children's Research Hospital",
            "LocationCity": "Memphis",
            "LocationState": "Tennessee",
            "LocationZip": "38105",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "ReferencesModule": {
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "St. Jude Children's Research Hospital",
            "SeeAlsoLinkURL": "http://www.stjude.org"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000010009",
            "ConditionMeshTerm": "Osteochondrodysplasias"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000001848",
            "ConditionAncestorTerm": "Bone Diseases, Developmental"
          },
          {
            "ConditionAncestorId": "D000001847",
            "ConditionAncestorTerm": "Bone Diseases"
          },
          {
            "ConditionAncestorId": "D000009140",
            "ConditionAncestorTerm": "Musculoskeletal Diseases"
          },
          {
            "ConditionAncestorId": "D000030342",
            "ConditionAncestorTerm": "Genetic Diseases, Inborn"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M12088",
            "ConditionBrowseLeafName": "Osteogenesis Imperfecta",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12084",
            "ConditionBrowseLeafName": "Osteochondrodysplasias",
            "ConditionBrowseLeafAsFound": "Osteodysplasia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11195",
            "ConditionBrowseLeafName": "Mucopolysaccharidosis IV",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4278",
            "ConditionBrowseLeafName": "Bone Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4279",
            "ConditionBrowseLeafName": "Bone Diseases, Developmental",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11249",
            "ConditionBrowseLeafName": "Musculoskeletal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22839",
            "ConditionBrowseLeafName": "Genetic Diseases, Inborn",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4306",
            "ConditionBrowseLeafName": "Osteogenesis Imperfecta",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3909",
            "ConditionBrowseLeafName": "Mucopolysaccharidosis Type IV",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC16",
            "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}